Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 2,850 shares of common stock at $70.91 per share. According to the filing, the shares were sold under an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a prior 26,000-RSU grant. After this transaction, Klein directly holds 394,070 shares, indicating a small, tax-driven reduction in his overall stake.
PTCT filed a Form 144 reporting planned or recent sales of Common Stock. The filing shows 2,850 shares tied to restricted stock vesting with an issuer compensation designation dated 04/20/2026. It also lists two dispositions in the past three months: 7,371 shares for $511,227.50 and 2,662 shares for $170,572.44. Shares outstanding are listed as 82,774,730 as of 04/21/2026.
PTC Therapeutics is holding its 2026 Annual Meeting of Stockholders virtually on June 2, 2026 at 9:00 a.m. Eastern Time via webcast at www.virtualshareholdermeeting.com/PTCT2026. Stockholders will vote on electing four Class I directors to terms ending in 2029, ratifying Ernst & Young LLP as independent auditor, and approving an advisory "say‑on‑pay" resolution for named executive officer compensation.
The record date is April 10, 2026, with 82,911,783 common shares outstanding, each entitled to one vote. The board reports that all directors except the CEO are independent, maintains a classified board structure, and emphasizes ESG, employee development, and diversity. Ernst & Young LLP billed audit and related services totaling $2.81 million in 2025, and the audit committee recommends ratification.
PTC Therapeutics executive Mark Elliott Boulding exercised stock options and sold shares in a pre-planned trade. He exercised options to acquire 2,265 shares of Common Stock at an exercise price of $39.42 per share and received 2,265 shares.
On the same date, he sold 822 shares at a weighted average price of $68.91 per share and 1,443 shares at a weighted average price of $69.75 per share, pursuant to a Rule 10b5-1 trading plan. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
PTC Therapeutics, Inc. executive Lee Scott Golden reported an automatic sale of 829 shares of Common Stock at $67.99 per share. According to the disclosure, these shares were sold pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 2,100 restricted stock units (RSUs) from an April 24, 2023 grant of 8,400 RSUs. Following this tax-related sale, Golden directly holds 79,115 shares of PTC Therapeutics common stock, so the transaction represents a small portion of his overall reported holdings.
PTCT notice under Rule 144 reporting proposed sale of 2,265 shares of Common Stock by issuance/option proceeds on 04/06/2026. The filing also lists multiple prior disposals by Mark Boulding in early 2026, including sales of 1,739, 4,879, 4,033, 2,314, 2,813, 3,081, and 3,019 shares on specific dates.
PTC Therapeutics, Inc. reported that Chief Technical Operations Officer Neil Gregory Almstead sold a total of 52,003 shares of common stock in open‑market transactions on 2026-04-01 at prices around $69 per share.
After these sales, he directly holds 60,137 shares of PTC Therapeutics common stock and indirectly holds 2,737 shares through his spouse. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
PTCT submitted a Form 144 notice reporting proposed resale activity in its Common Stock. The filing lists 829 shares tied to a restricted stock vesting on 04/01/2026 as securities to be sold. The filing also itemizes open-market dispositions by Lee S. Golden during the prior three months: 1,340, 642, 866, 2,484, and 10,000 shares with corresponding proceeds shown on the form.
PTCT insiders reported multiple restricted-stock vesting events and subsequent Rule 144 sales. The excerpt lists scheduled restricted-stock vesting entries across 2016–2025 and shows recent open-market sales by Neil G. Almstead and Zheng Y. Almstead on specific dates in 2026 with per-trade share counts and proceeds.